630125-96-1

Upstream product

• 75-44-5 phosgene 
• 105130-28-7 4-(6-Chloropyrimidin-4-yloxy)phenylamine 
• 100-02-7 4-nitro-phenol 
• 124041-03-8 4-chloro-6-(4-nitro-phenoxy)-pyrimidine 

Downstream Products

• 853298-86-9 1-(4-bromo-3-trifluoromethyl-phenyl)-3-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-urea 
• 853297-70-8 1-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-3-[4-(1-methyl-piperidin-4-yloxy)-3-trifluoromethyl-phenyl]-urea 
• 853297-55-9 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-[4-(4-ethylpiperazin-1-ylmethyl)-phenyl]-urea 
• 853296-82-9 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-[3-(azetidin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea 
• 853297-02-6 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-[4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-urea 
• 853296-86-3 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea 
• 853297-43-5 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-[4-(4,5-dimethylimidazol-1-ylmethyl)-3-trifluoromethyl-phenyl]-urea 
• 853297-46-8 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-[4-(2-methylimidazol-1-ylmethyl)-3-trifluoromethyl-phenyl]-urea 
• 853297-56-0 1-(4-[1,4']bipiperidinyl-1'-yl-3-trifluoromethyl-phenyl)-3-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-urea 
• 853297-59-3 1-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-3-{4-[4-(2,2-dimethyl-propyl)-piperazin-1-ylmethyl]-3-trifluoromethyl-phenyl}-urea 
• 853297-64-0 1-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-3-{4-[4-(2,2-dimethyl-propyl)-piperazin-1-yl]-3-trifluoromethyl-phenyl}-urea 
• 853297-67-3 1-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-3-[4-(1-methyl-piperidin-4-ylmethoxy)-3-trifluoromethyl-phenyl]-urea 
• 853297-71-9 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-{4-[2-(4-ethyl-piperazin-1-yl)-ethyl]-3-trifluoromethyl-phenyl}-urea 
• 853298-97-2 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-[4-(4-ethylpiperazin-1-ylmethyl)-3-chloro-phenyl]-urea 

Relevant academic research and scientific papers

DISUBSTITUTED UREAS AS KINASE INHIBITORS

The invention relates to compounds of the formula (I), their use as kinase inhibitors, new pharmaceutical formulations comprising said compounds, said compounds for use in the diagnostic or therapeutic treatment of warm-blooded animals, especially humans,

DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of diaryl urea derivatives for the manufacture of pharmaceutical compositions for the treatment of RET dependent disorders, especially RET dependent tumor diseases. The invention further relates to novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and their use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease, to pharmaceutical compositions comprising such novel N-[4-pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and to the use of such novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as tumour diseases.